Circulating Tumor Cells Were Associated with the Number of T Lymphocyte Subsets and NK Cells in Peripheral Blood in Advanced Non-Small-Cell Lung Cancer

Liang Ye, Fang Zhang, Huijuan Li, Linfei Yang, Tangfeng Lv, Wei Gu, Yong Song, Liang Ye, Fang Zhang, Huijuan Li, Linfei Yang, Tangfeng Lv, Wei Gu, Yong Song

Abstract

In this study, we aim to investigate the correlation between circulating tumor cells (CTCs) and the T lymphocyte subsets and NK cells in peripheral blood in non-small-cell lung cancer (NSCLC). The peripheral blood CTCs were determined by SET-iFISH. Flow cytometry was used to determine the distribution of T lymphocyte subsets and NK cells. Forty-one (49%) patients showed positivity for CTCs. Logistic regression analysis revealed CTC number was negatively correlated with the ratio of CD3+, CD4+, CD4+/CD8+, and NK % in patients at stage IV, while in a positive correlation was noticed between CTC number and regulatory T cell (Tregs) ratio in these patients. Multivariate analysis was performed in combination with the clinical-pathological materials to identify the risk factors for CTC positivity. Differentiation, NSCLC stage, percentages of CD3+CD4+ cells, Tregs, and NK cells were the independent risk factors for CTCs. CTCs were associated with the decrease of immune surveillance in the peripheral blood in NSCLC patients. The decrease of immune surveillance contributed to the escape of CTCs from the killing effects of the immunocytes, as well as the formation of metastasized lesions in the target organs.

Figures

Figure 1
Figure 1
Immunostaining of a single lung cancer CTC isolated from patient peripheral blood. The CTCs were observed through combining CD45, DAPI, and fluorescence in situ hybridization with the centromere of chromosome 8 (CEP8). CD45-DAPI+CEP8>2 was considered as CTC.

References

    1. Ferlay J., Shin H. R., Bray F., Forman D., Mathers C., Parkin D. M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. 2010;127(12):2893–2917. doi: 10.1002/ijc.25516.
    1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA: a Cancer Journal for Clinicians. 2014;64(1):9–29. doi: 10.3322/caac.21208.
    1. Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013.
    1. Kelsey C. R., Marks L. B., Hollis D., et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer. 2009;115(22):5218–5227. doi: 10.1002/cncr.24625.
    1. Bremnes R. M., Donnem T., Al-Saad S., et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. Journal of Thoracic Oncology. 2011;6(1):209–217. doi: 10.1097/JTO.0b013e3181f8a1bd.
    1. Maheswaran S., Haber D. A. Circulating tumor cells: a window into cancer biology and metastasis. Current Opinion in Genetics & Development. 2010;20(1):96–99. doi: 10.1016/j.gde.2009.12.002.
    1. O’Flaherty J. D., Gray S., Richard D., et al. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer. 2012;76(1):19–25. doi: 10.1016/j.lungcan.2011.10.018.
    1. Ignatiadis M., Lee M., Jeffrey S. S. Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility. Clinical Cancer Research. 2015;21(21):4786–4800. doi: 10.1158/1078-0432.CCR-14-1190.
    1. Krebs M. G., Sloane R., Priest L., et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. Journal of Clinical Oncology. 2011;29(12):1556–1563. doi: 10.1200/JCO.2010.28.7045.
    1. Grivennikov S. I., Greten F. R., Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi: 10.1016/j.cell.2010.01.025.
    1. Finn O. J. Cancer immunology. New England Journal of Medicine. 2008;358(25):2704–2715. doi: 10.1056/NEJMra072739.
    1. de la Cruz-Merino L., Grande-Pulido E., Albero-Tamarit A., Codes-Manuel de Villena M. E. Cancer and immune response: old and new evidence for future challenges. Oncologist. 2008;13(12):1246–1254. doi: 10.1634/theoncologist.2008-0166.
    1. Wernersson S., Pejler G. Mast cell secretory granules: armed for battle. Nature Reviews Immunology. 2014;14(7):478–494. doi: 10.1038/nri3690.
    1. Pahl J., Cerwenka A. Tricking the balance: NK cells in anti-cancer immunity. Immunobiology. 2017;222(1):11–20. doi: 10.1016/j.imbio.2015.07.012.
    1. Deepak P., Acharya A. Anti-tumor immunity and mechanism of immunosuppression mediated by tumor cells: role of tumor-derived soluble factors and cytokines. International Reviews of Immunology. 2010;29(4):421–458. doi: 10.3109/08830185.2010.483027.
    1. Durowicz S., Olszewski W. L., Dluzniewska J., Laszuk D., Lukomska B. Cytotoxic sinusoidal lymphocytes of liver transplant are effective against circulating tumor cells. Transplantation Proceedings. 1999;31(1-2):825–827. doi: 10.1016/S0041-1345(98)01789-8.
    1. Mego M., Gao H., Cohen E. N., et al. Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer. Journal of Cancer. 2016;7(9):1095–1104. doi: 10.7150/jca.13098.
    1. Reuben J. M., Lee B. N., Li C., et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 2006;106(11):2437–2444. doi: 10.1002/cncr.21854.
    1. Qiu H., Xiao-Jun W., Zhi-Wei Z., et al. The prognostic significance of peripheral T-lymphocyte subsets and natural killer cells in patients with colorectal cancer. Hepato-Gastroenterology. 2009;56(94-95):1310–1315.
    1. Tanaka F., Yoneda K., Kondo N., et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clinical Cancer Research. 2009;15(22):6980–6986. doi: 10.1158/1078-0432.CCR-09-1095.
    1. Chudasama D., Rice A., Soppa G., Anikin V. Circulating tumour cells in patients with lung cancer undergoing endobronchial cryotherapy. Cryobiology. 2015;71(1):161–163. doi: 10.1016/j.cryobiol.2015.06.001.
    1. Alama A., Truini A., Coco S., Genova C., Grossi F. Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. Drug Discovery Today. 2014;19(10):1671–1676. doi: 10.1016/j.drudis.2014.06.001.
    1. Dorsey J. F., Kao G. D., MacArthur K. M., et al. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: pilot study results. Cancer. 2015;121(1):139–149. doi: 10.1002/cncr.28975.
    1. Hou J. M., Krebs M., Ward T., et al. Circulating tumor cells as a window on metastasis biology in lung cancer. The American Journal of Pathology. 2011;178(3):989–996. doi: 10.1016/j.ajpath.2010.12.003.
    1. Gabrielson A., Wu Y., Wang H., et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunology Research. 2016;4(5):419–430. doi: 10.1158/2326-6066.CIR-15-0110.
    1. Morvan M. G., Lanier L. L. NK cells and cancer: you can teach innate cells new tricks. Nature Reviews Cancer. 2016;16(1):7–19. doi: 10.1038/nrc.2015.5.
    1. Zhang C., Xin H., Zhang W., et al. CD5 binds to interleukin-6 and induces a feed-forward loop with the transcription factor STAT3 in B cells to promote cancer. Immunity. 2016;44(4):913–923. doi: 10.1016/j.immuni.2016.04.003.
    1. Wolf D., Sopper S., Pircher A., Gastl G., Wolf A. M. Treg(s) in cancer: friends or foe? Journal of Cellular Physiology. 2015;230(11):2598–2605. doi: 10.1002/jcp.25016.
    1. Cerliani J. P., Dalotto-Moreno T., Compagno D., et al. Study of galectins in tumor immunity: strategies and methods. Methods in Molecular Biology. 2015;1207:249–268.
    1. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–489. doi: 10.1038/nature10673.
    1. Ohaegbulam K. C., Assal A., Lazar-Molnar E., Yao Y., Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine. 2015;21(1):24–33. doi: 10.1016/j.molmed.2014.10.009.
    1. Erfani N., Mehrabadi S. M., Ghayumi M. A., et al. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC) Lung Cancer. 2012;77(2):306–311. doi: 10.1016/j.lungcan.2012.04.011.
    1. Wang W. J., Tao Z., Gu W., Sun L. H. Variation of blood T lymphocyte subgroups in patients with non- small cell lung cancer. Asian Pacific Journal of Cancer Prevention. 2013;14(8):4671–4673. doi: 10.7314/APJCP.2013.14.8.4671.
    1. Wesselius L. J., Wheaton D. L., Manahan-Wahl L. J., Sherard S. L., Taylor S. A., Abdou N. A. Lymphocyte subsets in lung cancer. Chest. 1987;91(5):725–729. doi: 10.1378/chest.91.5.725.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit